APSR2026-696

Yes
Late-Breaking
Submitted
Oral Presentation
AO15-003
 
 
https://storage.unitedwebnetwork.com/files/1285/1220663-46903-APSR2026-696_439604.pptx
Format: PPTX Only
 
Format: PDF Only
02. Cell and Molecular Biology
6

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Akira Yamagata * Kyoto University Department of Clinical Application, Center for iPS Cell Research and Application (CiRA) Kyoto Japan Kyoto University Department of Respiratory Medicine, Graduate School of Medicine Kyoto Japan
Yusuke Tsutsui - Kyoto University Department of Clinical Application, Center for iPS Cell Research and Application (CiRA) Kyoto Japan Kyoto University Department of Drug Discovery for Lung Diseases, Graduate School of Medicine Kyoto Japan
Koji Tamai - Kyoto University Department of Clinical Application, Center for iPS Cell Research and Application (CiRA) Kyoto Japan Kyoto University Department of Drug Discovery for Lung Diseases, Graduate School of Medicine Kyoto Japan
Ryuta Mikawa - Kyoto University Department of Clinical Application, Center for iPS Cell Research and Application (CiRA) Kyoto Japan Kyoto University Department of Drug Discovery for Lung Diseases, Graduate School of Medicine Kyoto Japan
Satoshi Konishi - Kyoto University Department of Clinical Application, Center for iPS Cell Research and Application (CiRA) Kyoto Japan
Shimpei Gotoh - Kyoto University Department of Clinical Application, Center for iPS Cell Research and Application (CiRA) Kyoto Japan
 
 
 
 
 
 
 
 
 
Presenting Author Details
Akira
Yamagata
akira.y1122@gmail.com
+819051604773
31-40
Japan
Original Research
Therapeutic potential of human induced pluripotent stem cell-derived alveolar niche-like mesenchymal cells in pulmonary fibrosis
Maximum 25 words
Abstract Content
Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease with limited therapeutic options. Mesenchymal stromal cell therapies show promise but face challenges including limited proliferative capacity and donor heterogeneity. We recently established human induced pluripotent stem cell (hiPSC)-derived alveolar niche-like mesenchymal cells (iMES), which support alveolar organoid development and enable scalable production. This study evaluates the anti-fibrotic efficacy and therapeutic mechanisms of iMES in human in vitro and murine in vivo models of pulmonary fibrosis.
We utilized bleomycin (BLM)-induced pulmonary fibrosis models in two systems: a fibroblast-dependent alveolar organoid (FD-AO) model comprising hiPSC-derived alveolar type 2 (AT2) cells and human fetal lung fibroblasts, and both immunodeficient and immunocompetent mice. In the FD-AOs, the impact of iMES co-culture on fibrotic changes was assessed via gel contraction and transcriptomic profiling. In vivo, mice received intravenous iMES on days 1 and 4 post-BLM exposure. Efficacy was evaluated using histology, immunofluorescence, and pulmonary function tests. Biodistribution was tracked using bioluminescence imaging of Aka-luciferase-expressing iMES.
In the BLM-treated FD-AOs, iMES co-culture significantly suppressed gel contraction. RNA-seq revealed iMES downregulated extracellular matrix and myofibroblast-related markers in fibroblasts. Furthermore, iMES mitigated the aberrant induction of the profibrotic alveolar transitional cell state in epithelial cells while preserving AT2 cell characteristics. In both immunodeficient and immunocompetent BLM-mouse models, intravenous iMES administration significantly attenuated pulmonary collagen deposition, myofibroblast differentiation, and respiratory dysfunction. Bioluminescence imaging showed iMES rapidly accumulated in the lungs post-injection but diminished within 24 hours, indicating that they exert therapeutic effects without long-term engraftment.
iMES robustly attenuate pulmonary fibrosis in both human in vitro and mouse in vivo models by targeting fibroblast activation and epithelial differentiation abnormalities. Their potential scalability, immunological tolerance, and transient in vivo persistence provide therapeutic benefits without long-term engraftment risks. These characteristics position iMES as a promising and practical cell-based therapy for IPF.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
human induced pluripotent stem cell, mesenchymal cell, pulmonary fibrosis
maximum 3 keywords and no abbreviations, separated by commas
 
302